NCT00505687 - An Open-Label Extension Trial to Assess the Safety and Tolerability of Long Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG

Rotigotine

"Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours."

Trial Locations (26)

6020

Innsbruck

Unknown

Birmingham

St. Petersburg

Fort Wayne

Southfield

Forest Hills

Asheville

Raleigh

Houston

Milwaukee

Bochum

Dresden

Kassel

Ulm

Tel Aviv

Ancona

Lucca

Messina

Pretoria

Parow

Plumstead

Barcelona

Barncose Terrace

Bridgend

North Shields

Tyne and Wear